Clinical outcomes among individuals with a first episode psychosis attending Butabika National Mental Referral Hospital in Uganda: a longitudinal cohort study. A study protocol for a longitudinal cohort study.

BMJ Open
Dickens AkenaNoeline Nakasujja

Abstract

Psychotic disorders significantly contribute to high morbidity and mortality. In high-income countries, the predictors of mortality, relapse and barriers to care among patients with first episode psychoses (FEP) have been studied as a means of tailoring interventions to improve patient outcomes. However, little has been done to document relapse rates and their predictors in patients with FEP in low resourced, high disease burdened sub-Saharan Africa. We shall estimate the rates of relapse of psychotic symptoms and the factors that predict them in patients with FEP over 4 years. We will assemble a cohort of patients with an FEP seen at the Butabika National Mental Referral Hospital in Kampala over a 4-year period. Participants will be adults (≥18 years old), who have received a diagnosis of a psychosis according to the Mini International Neuropsychiatric Instrument (M.I.N.I.), with a demonstrable resolution of active symptoms following the use of antipsychotic medications, and deemed clinically stable for a discharge by the healthcare practitioner. All participants will be required to provide written informed consent. Trained research assistants will collect Demographic and clinical parameters, age of onset of symptoms, diagnost...Continue Reading

References

Nov 1, 1978·The British Journal of Psychiatry : the Journal of Mental Science·R C YoungD A Meyer
Jan 1, 1992·Psychological Medicine. Monograph Supplement·A JablenskyA Bertelsen
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 12, 2001·European Archives of Psychiatry and Clinical Neuroscience·A Jablensky
Dec 26, 2002·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Elliot M GoldnerJulian M Somers
May 27, 2005·PLoS Medicine·Sukanta SahaJohn McGrath
Jun 1, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Wulf RösslerAnita Riecher-Rössler
Nov 18, 2005·Health and Quality of Life Outcomes·Erin E MichalakRaymond W Lam
Jun 8, 2006·Psychological Medicine·N M MenezesR B Zipursky
Mar 24, 2007·Transcultural Psychiatry·Joanna TeutonChris Dowrick
Aug 8, 2007·Archives of General Psychiatry·Dilip V JesteHelena C Kraemer
Dec 1, 2007·Schizophrenia Bulletin·John McGrath
Nov 18, 2008·Schizophrenia Bulletin·Peter F BuckleyDavid J Castle
Nov 3, 2010·The British Journal of Psychiatry : the Journal of Mental Science·Samuli I SaarniJaana Suvisaari
Jun 17, 2011·The Cochrane Database of Systematic Reviews·Jun XiaMadhvi R Belgamwar
Oct 12, 2011·BMC Psychiatry·Solomon TeferraLars Jacobsson
May 2, 2012·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Elsje van der VenAshok K Malla
Nov 1, 2009·Early Intervention in Psychiatry·Nicholas J K BreitbordeScott W Woods
Nov 24, 2012·The British Journal of Psychiatry : the Journal of Mental Science·Lene Halling HastrupMerete Nordentoft
Mar 26, 2013·International Journal of Methods in Psychiatric Research·Michael LukasiewiczUNKNOWN Emblem Study Group
Jan 3, 2014·JAMA Psychiatry·Sarah M HartzUNKNOWN Genomic Psychiatry Cohort Consortium
May 24, 2014·European Psychiatry : the Journal of the Association of European Psychiatrists·S Frey
Jun 3, 2014·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Eva J BrandlDaniel J Müller
Feb 7, 2015·The British Journal of Psychiatry : the Journal of Mental Science·Abebaw FekaduTeshome Shibre
Jun 20, 2015·Schizophrenia Research and Treatment·Erika JääskeläinenJouko Miettunen
Sep 12, 2015·The Lancet. Psychiatry·Martha Ward, Benjamin Druss
Mar 10, 2016·Harvard Review of Psychiatry·Urs HeilbronnerThomas G Schulze
Feb 7, 2017·Industrial Psychiatry Journal·Chandra Kiran, Suprakash Chaudhury
Sep 2, 2017·World Journal of Diabetes·Aniyizhai AnnamalaiCenk Tek
Dec 8, 2017·JAMA Psychiatry·Hannah E JongsmaUNKNOWN European Network of National Schizophrenia Networks Studying Gene-Environment Interactions Work Package 2 (EU-GEI WP2) Group
Jan 6, 2018·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Charles LaidiUNKNOWN FACE-SCZ Group

❮ Previous
Next ❯

Software Mentioned

GAP
Neuro

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here